ImmuPharma PLC
  • Science
    • Our Science
    • Autoimmunity
      • P140
      • Type M & Diagnostic
    • Type 1 Diabetes
      • Kapiglucagon
    • Anti-infectives
      • BioAMB
      • BioCIN
    • Pipeline
  • Company
    • Mission
    • About Us
    • Our Team
    • ImmuPharma Biotech
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Advisers
    • Email Alert
  • Updates
    • Announcements
    • Interviews
    • In the Media
  • Contact

Announcements


ARCHIVES


2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

  • Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan

    Apr 23, 2014

    ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that Dr. Sylviane Muller was recently invited by the Immunology Frontier Research Center of Osaka University, an internationally renowned research center in the field of immunology, to hold a seminar on the approach of Lupuzor for…

  • ImmuPharma Sponsors the 2014 European Lupus Conference

    Apr 11, 2014

    ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it is sponsoring the forthcoming European Lupus Conference which takes place in Athens, Greece from April 23 – 26, 2014. The “European Lupus Meetings” is a major forum for all people interested in the disease:…

←Previous Page
  • AIM Rule 26
  • Contact information
  • Disclaimer
  • Privacy Policy

© ImmuPharma PLC 2005-2025 | All rights reserved